Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden

Molecular Psychiatry

Volumn 9, Issue 6, 2004, Pages 547-549+542

  Bart, G ^a   Heilig, M ^b   LaForge, K S ^a   Pollak, L ^b   Leal, S M ^c   Ott, J ^a   Kreek, M J ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR; NALTREXONE;

ADULT; ALCOHOLISM; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA ISOLATION; DNA POLYMORPHISM; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC CODE; HEREDITY; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RECEPTOR AFFINITY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

AMINO ACID SUBSTITUTION; EXONS; GENOTYPE; HEROIN DEPENDENCE; HUMANS; NUCLEAR FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; RISK FACTORS; SWEDEN;

EID: 3042781389     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001504     Document Type: Article

References (10)

1. Kreek MJ et al. Nat Rev Drug Disc 2002; 1: 710-726.
2. Tsuang MT et al. Arch Gen Psychiatry 1998; 55: 967-972.
3. LaForge KS et al. Eur J Pharmacol 2000; 410(2): 249-268.
4. Belknap JK et al. Ann NY Acad Sci 1992; 645: 311-323.
5. Matthes HWD et al. Nature 1996; 383: 819-823.
6. Becker A et al. Naunym-Schmiedebergs Arch Pharmacol 2000; 361: 584-589.
7. Bond C et al. Proc Natl Acad Sci USA 1998; 95: 9608-9613.
8. Wand GS et al. Neuropsychopharmacology 2002; 26: 106-114.
9. Hernandez-Avila CA et al. Am J Med Genet 2003; 118B: 60-65.
10. Oslin DW et al. Neuropsychopharmacology 2003; 28: 1546-1552.